Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease - sprookjes - yvandenbroek - TriplyDB

Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease

Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease

http://www.wikidata.org/entity/Q41849847

about

Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.Cholinergic modulation of narcoleptic attacks in double orexin receptor knockout mice REAC technology modifies pathological neuroinflammation and motor behaviour in an Alzheimer's disease mouse model Neuroprotective effects of donepezil against cholinergic depletion.Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism.The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.Computational identification of potential multitarget treatments for ameliorating the adverse effects of amyloid-β on synaptic plasticity Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics Human reversal learning under conditions of certain versus uncertain outcomes Fructus mume extracts alleviate cognitive impairments in 5XFAD transgenic mice Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome.Phenserine.Anti-dementia drugs and hippocampal-dependent memory in rodents.Amyloid-cholinesterase interactions. Implications for Alzheimer's disease.Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease.Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.Xanthoceraside modulates neurogenesis to ameliorate cognitive impairment in APP/PS1 transgenic mice.Translational Assays for Assessment of Cognition in Rodent Models of Alzheimer's Disease and Dementia.Mesenchymal Stem Cell Transplantation Promotes Neurogenesis and Ameliorates Autism Related Behaviors in BTBR Mice.Increasing hippocampal acetylcholine levels enhance behavioral performance in an animal model of diencephalic amnesia.Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease A computer-automated touchscreen paired-associates learning (PAL) task for mice: impairments following administration of scopolamine or dicyclomine and improvements following donepezil.CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice.β-Amyloid pathology alters neural network activation during retrieval of contextual fear memories in a mouse model of Alzheimer's disease.Potentiation of Acetylcholine-Mediated Facilitation of Inhibitory Synaptic Transmission by an Azaindolizione Derivative, ZSET1446 (ST101), in the Rat Hippocampus.Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease.Administration of donepezil does not rescue galanin-induced spatial learning deficits.Use of behavioural and long-term potentiation models in the development of memory-improving drugs.MK-801-induced learning impairments reversed by physostigmine and nicotine in zebrafish

P2860

Q26858963-12FAC3A4-E19F-4D36-A3ED-95D42792D718 Q27347659-E6AEA35E-3619-4F1E-8C46-D13848D2F639 Q30371534-10D222C5-EE69-49BE-8442-A7242474B28A Q30440321-340035D5-AB94-4BF5-B688-9375DD727CB1 Q30571888-277C79CB-2F23-46AB-BEE0-5966292AF2F1 Q30577199-6CDCC255-2DBD-4CFE-88ED-F6B1EE2503F8 Q33611723-F7CAC7CD-2C90-4468-A23E-3575028103B0 Q34418781-66D99BDA-9760-4887-A4C2-2BE960F6A471 Q34965949-B766663A-B0F5-470F-9CF2-AEDCA6BD0907 Q34988702-C087B43A-FAE8-459E-BA86-2DE87923D4BD Q35916667-4B377AA3-562C-43C9-A8AF-E69D746F5C40 Q36465744-931E54F1-0E39-48A5-90AD-00BD33C1D1A0 Q36861622-FC4B53E0-A5C7-4D30-88DA-5C5C31E71DFB Q36925129-943DB127-5FAA-41A9-9706-FB9E8A26DD92 Q37060531-855CC90D-C0A9-493D-9C38-EB567B9851F2 Q37148525-99B0A844-E59D-47FE-AAB8-86C2A0047018 Q37461883-40784449-62B6-4230-AB8E-B93E066D3DE8 Q37548320-599744F8-182D-4344-8CB8-3AD9CE2EEE02 Q38661043-6E963D6B-B6DF-445C-A519-37135CEE3E00 Q38956724-94DCDDEB-EBDE-48F3-9C36-7D27332708BF Q38976018-25BAE411-42BE-448E-9CE4-99600504EB09 Q41886983-CE6AC930-F48E-44D0-B42A-E38B235DA813 Q42557471-DE8DAF5D-4943-42DC-9355-A6569D16D122 Q42803197-8C48B2DC-60DE-4538-9CE0-AFBE262DD7A5 Q45912487-9A2C0A1B-CC2D-415C-9701-83C738E93DDC Q47904278-988E55A5-0DE9-4772-B66F-CB4FD4577964 Q50549198-BF3B368B-B8D7-4DC0-9BE5-40F3ED663895 Q50738123-B61BDA55-98D1-46E7-8C84-20F466EB0ECF Q50790052-29B032F6-7317-4CA6-90E7-419315F5F5E0 Q51962312-678B47F0-417C-4669-842A-73663C36A0D9 Q58172497-68BE7AC2-F51F-4E18-87E2-979B01047E78

P2860

Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease

http://www.wikidata.org/entity/Q41849847

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Acetylcholinesterase inhibitor ...... e model of Alzheimer's disease

@en

type

label

Acetylcholinesterase inhibitor ...... e model of Alzheimer's disease

@en

prefLabel

Acetylcholinesterase inhibitor ...... e model of Alzheimer's disease

@en

P1433

Q41849847-DA1D75F6-56BE-4AA4-8C3C-3D5BB99F3557

P1476

Q41849847-ED19B03A-C902-4139-8F0D-57F6B661E464

P2093

Q41849847-267E17E8-5713-40F3-B7C5-77EF6398A1E9

Q41849847-CD889750-625E-4DC5-BECB-D4372DAB5B48

Q41849847-CE480B4E-A636-4715-893E-A30AB7840D5B

Q41849847-D9138F4B-459F-4F87-9BD2-27C54350217C

Q41849847-EA4E22B2-FFEC-4A4A-B9D9-260DDF63EB7C

Q41849847-FD28FFEC-35CF-42CB-9018-D4CBA1BAD6FB

P2860

Q41849847-0B56B974-9D01-47F4-9F44-F6F243FE630D

Q41849847-0BBEDB80-3379-4ED4-970B-52AB8328E0D8

Q41849847-11571B7D-EAB1-4B8A-B676-3CF3BF40A71D

Q41849847-123876B6-EB45-4C30-A345-7CDAE2F50076

Q41849847-242567F9-89FE-4D1F-934B-DB8C97C48E90

Q41849847-30E33C30-AF1E-41B8-8573-4A21A5999F26

Q41849847-39382BB0-915F-47F5-B4B1-CC938352E778

Q41849847-3953F59A-64EF-47FA-B36F-5603B72B4670

Q41849847-401CCCB4-92B6-4EC4-841D-C2D9006A2DF8

Q41849847-4531087D-930E-4369-B2D2-BF1EB1ADCCB4

P2888

Q41849847-DB8A88ED-6767-4BAC-8FE3-12D504FD4CF5

P304

Q41849847-76A66E07-D6C5-4F30-9F2D-55EC17E46EB6

P31

Q41849847-47DA8EAB-1DED-49B6-A11B-63E5FCCE3F7F

P356

Q41849847-07D0B6FC-8667-4D57-AC36-F9081BA9276A

P433

Q41849847-64EA794F-D7CF-4CCD-B29D-88AA02CDC35D

P478

Q41849847-C50FE9A6-81BB-47FF-8857-B228868CFD66

P577

Q41849847-833976E4-9CFF-446F-95F1-209DEFD34229

P5875

Q41849847-35F61BD6-AB87-4E14-8F4A-06F772AC5118

P6179

Q41849847-9E225AE5-5BEC-467C-8684-7CB66BFD2701

P698

Q41849847-9201FAB8-08F3-4F9C-912D-D65A32E7A601

P921

Q41849847-90698899-56E6-430A-B4B0-879508954DE2

P932

Q41849847-9288AE34-0668-47AE-B684-A9D1BB738111

P356

S00213-005-2230-6

P1433

Psychopharmacology

P1476

Acetylcholinesterase inhibitor ...... e model of Alzheimer's disease

@en

P2093

Amy Bertchume

http://www.w3.org/2001/XMLSchema#string

Cynthia A Csernansky

http://www.w3.org/2001/XMLSchema#string

Dana Vallera

http://www.w3.org/2001/XMLSchema#string

Hongxin Dong

http://www.w3.org/2001/XMLSchema#string

John G Csernansky

http://www.w3.org/2001/XMLSchema#string

Maureen V Martin

http://www.w3.org/2001/XMLSchema#string

P2860

The cholinergic hypothesis of Alzheimer's disease: a review of progress

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein

The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

Learning and memory in transgenic mice modeling Alzheimer's disease.

Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss

Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology.

P2888

s00213-005-2230-6

P304

145-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00213-005-2230-6

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

181

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7955931

http://www.w3.org/2001/XMLSchema#string

P6179

1029147515

http://www.w3.org/2001/XMLSchema#string

P698

15778881

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1361685

http://www.w3.org/2001/XMLSchema#string